Respiratory distress observation scales to predict weaning outcome

Maxens Decavèle, Emmanuel Rozenberg, Marie-Cécile Niérat, Julien Mayaux, Elise Morawiec, Capucine Morélot-Panzini, Thomas Similowski, Alexandre Demoule and Martin Dres

Abstract

Background: Whether dyspnea is present before starting a spontaneous breathing trial (SBT) and whether it may affect the outcome of the SBT is unknown. Mechanical Ventilation—Respiratory Distress Observation Scale (MV-RDOS) has been proposed as a reliable surrogate of dyspnea in non-communicative intubated patients. In the present study, we sought (1) to describe the evolution of the MV-RDOS during a SBT and (2) to investigate whether MV-RDOS can predict the outcome of the SBT.

Methods: Prospective, single-center study in a twenty-two bed ICU in a tertiary center. Patients intubated since more 48 h who had failed a first SBT were eligible if they meet classical readiness to wean criteria. The MV-RDOS was assessed before, at 2-min, 15-min and 30-min (end) of the SBT. The presence of clinically important dyspnea was inferred by a MV-RDOS value \( \geq 2.6 \).

Results: Fifty-eight patients (age 63 [51–70], SAPS II 66 [51–76]; med [IQR]) were included. Thirty-three (57%) patients failed the SBT, whose 18 (55%) failed before 15-min. Twenty-five (43%) patients successfully passed the SBT. A MV-RDOS \( \geq 2.6 \) was present in ten (17%) patients before to start the SBT. All these ten patients subsequently failed the SBT. A MV-RDOS \( \geq 2.6 \) at 2-min predicted a SBT failure with a 51% sensibility and a 88% specificity (AUC 0.741 95% confidence interval [CI] 0.616–0.866, \( p = 0.002 \)). Best cut-off value at 2-min was 4.3 and predicted SBT failure with a 27% sensibility and a 96% specificity.

Conclusion: Despite patients met classical readiness to wean criteria, respiratory distress assessed with the MV-RDOS was frequent at the beginning of SBT. Measuring MV-RDOS before to initiate a SBT could avoid undue procedure and reduce patient’s exposure to unnecessary mechanical ventilation weaning failure and distress.

Keywords: Critical care, Dyspnea, Dyspnea observation scale, Respiratory Distress Observation Scale, Intensive care unit, Spontaneous breathing trial, Weaning from mechanical ventilation

Background

The decision to extubate poses critical challenges. Delaying extubation exposes patients to undue prolongation of mechanical ventilation [1] and the ensuing complications whereas extubation failure increases morbi-mortality [2]. The decision to extubate comes after a patient has been considered "ready to wean" [1] and at the end of a spontaneous breathing trial (SBT) mimicking the post-extubation load-capacity balance of the respiratory system. Judging readiness to wean and SBT outcome are difficult, as demonstrated by discrepancies in clinicians’ assessments [3, 4] and high incidences of SBT and extubation failure [3–5]. To diagnose SBT failure, international recommendations suggest relying on objective criteria such as respiratory rate, heart rate or arterial blood gases. However, it is well established that the separation from
the ventilator is often based on subjective grounds, with
a frequent natural tendency for clinicians to keep their
patients on the "safe" side, i.e., considering them as not
being ready for separation [6]. Only very few studies have
investigated the patients’ subjective perception of autono-
umous breathing [7]. This is surprising since dyspnea, a
cardinal symptom of respiratory distress may behave as
a warning signal suggesting that patients are not ready to
undergo a SBT.

Dyspnea corresponds to the self-report of a bothering
or distressing awareness of breathing activity [8]. It
is considered to result from an imbalance between the
outflowing neural drive to breathe—the "demand," from
the brain—and the corresponding instreaming afferent
return—the "supply," from the respiratory system—(cor-
ollary discharge theory) [9]. This can typically result from
an unfavorable respiratory system load-capacity bal-
ance, as it occurs in cases of SBT failure [10]. The associ-
between dyspnea and SBT failure has indeed been
reported [11–15], as well as post-extubation dyspnea is
predictive of extubation failure [16].

Yet, assessing dyspnea in intubated mechanically venti-
lated patients is not straightforward. Self-report implies
patient cooperation, which is often not possible in this
setting [17]. Subjective nonself evaluation of dyspnea is
unreliable [11, 18, 19]. In addition, dyspnea is multi-
dimensional in essence, a characteristic not captured by the
numerical rating scales typically used in the clinical field
[8]. Respiratory distress observation scales (RDOS) were
developed to obviate these limitations, in palliative care
medicine [20], upon admission to the intensive care unit
(IC-RDOS [21]) or under mechanical ventilation (MV-
RDOS [22]). These scales rely on assessing a multidimen-
sional ensemble of measurable physical and behavioral
manifestations related to respiratory suffering [18], corre-
late with dyspnea in communicative patients [20–22] and
provided standardized way to infer dyspnea in noncom-
unicative patients.

The present study was designed to test the hypothesis
that MV-RDOS would be valuable to refine readiness
to wean criteria and predict SBT failure. The objective
was to measure MV-RDOS before starting the SBTs in
patients meeting readiness to wean criteria, and to repeat
this evaluation at 2 min-SBT, 15 min-SBT and 30 min-
SBT (SBT end). We confronted the corresponding mea-
surements with SBT outcomes.

**Patients and methods**

**Study design and settings**

We assessed unpublished data from a previous a sin-
gle-center prospective weaning study [23] that was
approved by the Comité de Protection des Personnes
du Sud Ouest et Outre Mer 4 (RCB ID: 2018-A00176-
49). Written and oral information about the study was
given to patients or their families prior enrolment.
Informed consent was obtained from all patients or
their relatives. The present reporting complies with the
Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) Statement.

Patients were eligible for participation if they met
all the following criteria: (1) mechanical ventilation
via an endotracheal tube for more than 48 h, (2) fail-
ture to a first SBT, (3) readiness-to-wean criteria on the
day of inclusion defined as follows: (1) adequate motor
responses to simple verbal commands, (2) SpO2 > 90%-
or PaO2/FiO2 ≥ 150 mmHg with a fraction of inspired
oxygen (FiO2) ≤ 40% and (3) positive end-expiratory
pressure ≤ 8 cmH2O (4) heart rate < 140 beats/min and
respiratory rate < 35 cycles/min [1]. Patients younger
than 18, pregnant women, and patients in whom wean-
ing was impossible (pre-existing neuromuscular dis-
orders, cervical cord injury) were not considered for
inclusion.

**Data collection and respiratory distress assessment**

Physiological variables such as respiratory rate, heart
rate, systolic blood pressure, SpO2 and Glasgow coma
scale were recorded before and at the end of the SBT.
Arterial blood gas analyses were sampled before and at
the end of the SBT according to local practices.

A single investigator E.R evaluated in real time the
MV-RDOS (see below) and the Rapid shallow breathing
index (RSBI). The MV-RDOS is a 5-items "respira-
tory distress observation scale" specifically designed
for and validated in mechanically ventilated patients.
MV-RDOS items comprise respiratory rate, use of neck
muscles during inspiration, inward abdominal motion
during inspiration (abdominal paradox), heart rate, and
facial expression of fear. MV-RDOS is strictly clinical,
standardized, and does not require patient coopera-
tion. In communicative ICU patients, a MV-RDOS of
2.6 predicts a dyspnea visual analog scale > 30 mm with
a 57% sensitivity, a 94% specificity, and an AUC of 0.782
(95% CI 0.581–0.982) [22], noting that a dyspnea vis-
ual analog scale (VAS) > 30 mm is considered clinically
important [24]. MV-RDOS was only gathered by the
investigator for research purpose and not for clinical
decision-making. The MV-RDOS was thus presented
using its raw values and was also dichotomized around
its 2.6 threshold value that corresponds to a high prob-
ability of clinically important self-reported dyspnea.

The RSBI defined by the respiratory rate/tidal vol-
ume ratio (R/VT) was continuously obtained from the
ventilator.
**Study design**
Patients enrolled in the study underwent a 30-min SBT (shorter in case of obvious clinical intolerance) with pressure support and positive end-expiratory pressure set to zero, while FiO₂ remained unchanged [25, 26]. SBT failure was defined by the occurrence of at least one of the following objective criteria: respiratory rate ≥ 35 breaths/min or increase ≥ 50% from baseline, SpO₂ ≤ 90% or PaO₂ ≤ 50 mmHg with FiO₂ ≥ 50%, PaCO₂ > 50 mmHg, heart rate ≥ 140 bpm, de novo supraventricular or ventricular arrhythmia, systolic arterial pressure > 180 or < 90 mmHg, or alteration of consciousness [1].

After obtaining consent and before starting the SBT, MV-RDOS and the rapid shallow breathing index (RSBI, \( fR/VT \)) were collected. Then, the SBT started. MV-RDOS and RSBI were then evaluated at the second minute, at the fifteenth minute and at the end of the SBT or earlier in case of failure.

**Statistical analysis**
Continuous variables were expressed as median (interquartile range) and categorical variables were expressed as absolute and relative frequencies. Continuous variables were analyzed by Mann–Whitney test and categorical variables were compared using the Chi²-test or Fisher's exact test depending on the number of categories per variable. The MV-RDOS and RSBI values before, at 2-, 15- and 30-min of SBT were compared using a non-parametric analysis of variance test followed by Dunn's multiple comparison test. The performance of the MV-RDOS to discriminate SBT failure and success was tested before, at 2- and at 15-min of SBT by generating receiver operating curves (ROC), which were compared to the ROC of the RSBI. At same time points, sensitivity and specificity were calculated for the MV-RDOS cut-off value of 2.6 (representing clinically important self-reported dyspnea) as well as the best MV-RDOS and RSBI sensitivity and specificity according to the highest likelihood ratio. Analyses were performed using Prism 9.3.0 software (GraphPad Software, USA).

**Results**

**Characteristics of the patients and SBT outcome**
During the study period, 794 patients were admitted to the ICU and 340 received invasive mechanical ventilation. Among these 340 patients, 60 were enrolled in the study but 58 were analyzed because of missing data in the MV-RDOS calculation in two patients.

Table 1 presents the main characteristics of the patients. Thirty-three (57%) of the 58 patients enrolled in the study failed the SBT (Fig. 1). Among these 33 patients who failed the SBT, 18 (55%) failed before 15-min, 1 (3%) failed between 15- and 30-min and 14 (42%) failed at 30-min (Fig. 1). Except a lower PaO₂/FiO₂ ratio and a higher proportion of cardiac arrest as reason for intubation in patients who succeed, no difference was found among characteristics at inclusion between patients who succeed the SBT and their counterparts (Table 1). Details on the distribution of SBT failure criteria are reported in Additional file 1: Table S1.

**Respiratory distress assessment before starting the spontaneous breathing trial**
Before the SBT, the MV-RDOS and RSBI were, respectively, 2.2 (2.0–2.3) and 47 (34–66). The MV-RDOS was 2.1 (2.0–2.2) in patients who succeeded and 2.3 (2.0–2.6) in those who failed (\( p = 0.014 \)). A MV-RDOS ≥ 2.6 was present in ten patients (17%) before starting the SBT. All these patients subsequently failed the SBT.

The RSBI was also significantly lower in patients who succeeded than in the counterparts (37 [29–54] vs. 56 (39–73), \( p = 0.010 \)).

**MV-RDOS assessment over the spontaneous breathing trial**
At 2-min after the beginning of the SBT, 21 (36%) patients had a MV-RDOS ≥ 2.6 although no objective SBT failure criteria were present. Among these 21 patients, 18 (86%) subsequently failed the SBT. At 15-min of SBT, in 21 (53%) patients, the MV-RDOS was higher to 2.6 while no objective SBT failure criteria were present. Among these 21 patients, 12 (57%) subsequently failed the SBT. At 30-min of SBT (end), 22 (56%) patients had a MV-RDOS ≥ 2.6 without presenting objective SBT failure criteria. Among these 22 patients, 12 (55%) failed the SBT (Fig. 1).

The MV-RDOS significantly increased during the SBT in patients who failed (\( p < 0.001 \)) whereas it did not significantly vary in patients who successfully passed (\( p = 0.831 \)) the SBT (Fig. 2). MV-RDOS and RSBI values over the SBT are available in Table 2 and Additional file 1: Table S2.

**Prediction of SBT outcome according to MV-RDOS values**
Figure 3 represents the performances of the MV-RDOS to predict the SBT failure, at different time points of the SBT. A MV-RDOS ≥ 2.6 before SBT predicted a SBT failure with a 30% sensibility and a 100% specificity (AUC 0.690 95% confidence interval [CI] 0.553–0.824, \( p = 0.015 \)). Best cut-off value (highest likelihood ratio) before SBT was 2.4 and predicted SBT failure with a 36% sensibility and a 96% specificity.

A MV-RDOS of 2.6 at 2-min predicted a SBT failure with a 51% sensibility and a 88% specificity (AUC 0.741 95% confidence interval [CI] 0.616–0.866, \( p = 0.002 \)). Best cut-off value at 2-min was 4.3 and predicted SBT failure with a 27% sensibility and a 96% specificity.
A MV-RDOS of 2.6 at 15-min predicted a SBT failure with a 87% sensitivity and a 68% specificity (AUC 0.783 95%CI 0.642–0.924, \( p = 0.003 \)). Best cut-off value at 15-min was 4.5 and predicted SBT failure with a 40% sensitivity and a 96% specificity.

At each time points, the MV-RDOS performance to predict a SBT failure was similar to that of the RSBI (Fig. 3). Before SBT, best cut-off value of RSBI was 71 and predicted SBT failure with a 40% sensitivity and a 96% specificity. At 2-min, best cut-off value of RSBI was 84 and predicted a SBT failure with a 33% sensitivity and a 92% specificity. At 15-min best cut-off value of RSBI was 96 and predicted a SBT failure with a 46% sensitivity and a 96% specificity.

**Discussion**

The main findings can be summarized as follows: (1) almost 20% of patients, yet clinically deemed ready to undergo a SBT, had a MV-RDOS \( \geq 2.6 \) suggesting a high probability of clinically important dyspnea (VAS\( >30 \) mm), (2) 100% of these patients with a MV-RDOS \( \geq 2.6 \) before SBT subsequently failed the SBT, (3) an early MV-RDOS assessment at 2-min and 15-min SBT could predict SBT failure with a high specificity.

**Prevalence and significance of respiratory distress before SBT**

Observational studies of intubated patients in the ICU setting show a 40% prevalence of self-reported dyspnea (5 [4–7] on a 0–10 VAS) on the first day on which patient were able to communicate [27, 28]. The inferred prevalence of clinically important dyspnea (MV-RDOS \( \geq 2.6 \)) observed in our study is roughly two-fold lesser (17%). This could be explained by the fact in our study, patients were enrolled at a more clinically stable stage of their disease and were not yet facing the SBT asphyxial threat. Indeed, at the end of the SBT, clinically important dyspnea was finally suspected (MV-RDOS \( \geq 2.6 \)) in 56% of patients, which is in line with the previously reported proportion of patient with self-reported dyspnea \( \geq 4 \) at the end of a 30-min SBT (62%) [11].

**Table 1 Characteristics of the patients**

| Variables                                      | All patients (\( n = 58 \)) | SBT success (\( n = 25 \)) | SBT failure (\( n = 33 \)) | \( P \) value |
|------------------------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------|
| Age, years                                     | 62 (51–68)                    | 62 (50–73)                  | 63 (52–68)                  | 0.922        |
| Gender (male), n (%)                           | 31 (53)                       | 15 (60)                     | 16 (48)                     | 0.384        |
| Body mass index, kg/m²                         | 25 (21–29)                    | 25 (20–31)                  | 24 (21–29)                  | 0.782        |
| Comorbidities                                  |                               |                             |                             |              |
| Arterial hypertension, n (%)                   | 21 (36)                       | 9 (36)                      | 12 (36)                     | 1.000        |
| COPD, n (%)                                    | 11 (19)                       | 5 (20)                      | 6 (18)                      | 1.000        |
| Diabetes, n (%)                                | 11 (19)                       | 4 (16)                      | 7 (21)                      | 0.742        |
| Chronic kidney failure                         | 9 (16)                        | 5 (20)                      | 4 (12)                      | 0.479        |
| Reasons for ICU admission                      |                               |                             |                             |              |
| Acute respiratory failure, n (%)               | 33 (57)                       | 15 (60)                     | 18 (54)                     | 0.678        |
| Coma, n (%)                                    | 13 (22)                       | 6 (24)                      | 7 (21)                      | 1.000        |
| Cardiac arrest, n (%)                          | 8 (14)                        | 2 (8)                       | 6 (18)                      | 0.001        |
| Other, n (%)                                   | 4 (7)                         | 2 (8)                       | 2 (6)                       | 1.000        |
| Clinical variables                             |                               |                             |                             |              |
| Length of MV, days (at inclusion)              | 5 (2–7)                       | 3 (2–6)                     | 5 (2–11)                    | 0.315        |
| Number of previous SBT (at inclusion)          | 1 (1–1)                       | 1 (1–1)                     | 1 (1–1)                     | 0.731        |
| SAPS II (at admission)                         | 63 (49–76)                    | 57 (46–75)                  | 66 (50–76)                  | 0.388        |
| SOFA (at admission)                            | 10 (7–12)                     | 10 (7–11)                   | 10 (7–12)                   | 0.591        |
| Readiness to wean assessment at inclusion      |                               |                             |                             |              |
| Heart rate, beats/min                          | 93 (84–100)                   | 92 (79–101)                 | 93 (84–99)                  | 0.735        |
| Systolic arterial blood pressure, mmHg         | 132 (116–145)                 | 125 (111–141)               | 140 (117–152)               | 0.094        |
| Bicarbonate, mmol/L                            | 27 (23–31)                    | 25 (19–29)                  | 28 (24–32)                  | 0.105        |
| PaO2/FiO2                                      | 248 (178–329)                 | 315 (211–355)               | 230 (157–285)               | 0.014        |
| Positive end-expiratory pressure, cmH2O        | 5 (5–6)                      | 5 (5–6)                     | 6 (5–6)                     | 0.092        |
| Respiratory rate, breaths/min                  | 22 (17–27)                    | 19 (16–25)                  | 22 (17–29)                  | 0.189        |
| Expired tidal volume, ml/IBW                   | 6.9 (6.2–8.4)                 | 7.0 (6.6–9.2)               | 6.8 (5.8–8.2)               | 0.167        |

COPD, chronic obstructive pulmonary disease; fR, respiratory rate; VT, expired tidal volume; SBT, spontaneous breathing trial; SAPS II, Simplified Acute Physiology Score (SAPS) II; SOFA, Sequential Organ Failure Assessment
Our study showed that the MV-RDOS provides a standardized assessment of respiratory distress before SBT which, once detected, allowed to identify patients with a particularly high risk of SBT failure. To the best of our knowledge, this is the first study that evaluate the performance of a respiratory distress assessment to predict the SBT outcome. Although two items of the MV-RDOS, the heart and breathing rate, are present in the readiness-to-wean current criteria, only their threshold values are retained in the guidelines (i.e., heart rate ≥ 140 beats/min, respiratory rate ≥ 35 cycles/min). Here, the MV-RDOS allowed to integrate all absolute values of the heart and respiratory rate irrespective of any threshold values.

**Evolution of respiratory distress across the SBT**

In our study the MV-RDOS dramatically increased over the SBT in patients who failed the SBT. The asphyxial threat induced by the SBT, especially in those who failed, induce an innate array of multidimensional behaviors that have previously been investigated [29–31]. Schematically, these include signs of autonomic system activation (heart rate), respiratory drive increase (respiratory rate, abdominal paradox, use of neck muscle) or emotional response (facial expression of fear). This twofold increase in MV-RDOS at 15-min SBT in patients who failed the SBT is in line with the two-fold increase observed in the RDOS at 15-min SBT in patients with terminal ventilator withdrawal [30]. In another study, including patient who already presented sign of respiratory distress during a previous SBT, the use of neck muscle, the abdominal paradox and a fearful facial expression were observed during the second SBT in 58%, 33% and 58% of cases, respectively. These incidences were similar to that observed in our study except for the fearful facial expression which was less frequently observed in our study. This last point could be explained, at least partially, by the observer/investigator subjectivity or empathy variability between studies [18, 32]. All these three manifestations of respiratory suffering generally appeared before the first five minutes of SBT [29, 30], as observed in our study, supporting the relevance of using the MV-RDOS even at very early SBT stage. A physiological study reported that neck muscle electromyographic activity significantly increased during the first minute of patients who failed the SBT [33]. In addition, all the 5 items of the MV-RDOS significantly increased across the SBT, supporting also the clinical relevance of each separate item of the scale.

**Clinical implications**

According to guidelines, the assessment of readiness to wean, a crucial step in the weaning process, relies on a checklist of objective criteria [1]. This is
however surprising that patient’s dyspnea is not taking into account when deciding to initiate a SBT. Our study shows that a significant proportion of patients (almost 20%) exhibited MV-RDOS \( \geq 2.6 \) (suggesting clinically important dyspnea) before starting the SBT. It is also a major result that all these patients subsequently failed the SBT suggesting that they were exposed to an unnecessary respiratory suffering [17] recently demonstrated to be associated with the occurrence of post-traumatic stress disorder [28]. This lack of recognition of dyspnea is probably explained by the difficulty to obtain a reliable assessment of patient’s dyspnea in the ICU [28]. Using hetero-evaluation scales may help to address this issue. Systematic assessment of respiratory distress using the MV-RDOS before the SBT may help to refine the readiness-to-wean criteria. A MV-RDOS value \( \geq 2.6 \) could be used to not initiate or promptly stop the SBT because it corresponds to clinically important dyspnea and suffering. In the case of pain, an intensity rating \( \geq 4 \) is also the lower cut-off for “moderate-to-severe pain” and constitutes a clear indication for prompt analgesic prescription [34] and it seems obvious to stop muscle rehabilitation in case of pain during exercise. The particularly high specificity of MV-RDOS value \( > 4 \) (accompanied with modest sensitivity) may be helpful for clinical decision making regarding this goal of care of minimizing traumatic experiences induced by respiratory suffering [35] even more as less demanding weaning strategies are not necessarily associated with lower rates of successful weaning [36].

**Limitations**

This study has several limitations. Firstly, self-reported dyspnea was not measured, and it would have been interesting to confront dyspnea and MV-RDOS performances to predict SBT outcomes. However, MV-RDOS strongly correlates with dyspnea [22] and contrarily to self-reported dyspnea (unidimensional assessment of dyspnea intensity by numerical rating scales), MV-RDOS integrates the multiple dimensions of respiratory suffering and could be reach in every patient irrespective of their self-report capabilities. Secondly, this study was conducted exclusively in patients who already failed at least

---

*Fig. 2 Evolution of the Mechanical Ventilation—Respiratory Distress Observation Scale (MV-RDOS, Panel A) and all its components during the spontaneous breathing trial (SBT) between patients who succeeded (Panel B) or failed (Panel C) the SBT. *\( p < 0.05 \), **\( p < 0.001 \)
one SBT since these patients represented a priori greater clinical challenge. This limits the generalizability of our results and further studies are warranted in patients who never attempt yet a SBT. Thirdly, RSBI median values in our study were lower than that reported in the princeps study by Tobin et al., but in this study simple-to-wean patients were included, RSBI predicted extubation failure (not SBT failure) and currently median RSBI value in patients who failed the SBT is around 85 [37]. Fourthly, although MV-RDOS provide standardization in clinical assessment of respiratory distress, assessment of facial expression of fear and paradoxical motion of the abdomen during inspiration may vary between observers. Inter-rater reliability has not been assessed in this exploratory study. Finally, RSBI provided also good performances to predict SBT outcomes and contrarily to the MV-RDOS its assessment is entirely objective. However, beyond the prediction of the SBT outcome, the MV-RDOS allows to identify or strongly suspect a major patient-centered outcome—dyspnea—and when

| Variables of respiratory distress assessment | All patients (n = 58) | SBT success (n = 25) | SBT failure (n = 33) | P value |
|---------------------------------------------|----------------------|---------------------|---------------------|--------|
| **Before SBT (n = 58)**                     |                      |                     |                     |        |
| fR/V T, breaths/min/L                       | 47 (34–66)           | 37 (29–54)          | 56 (39–73)          | 0.010  |
| MV-RDOS ≥ 2.6, n (%)                        | 10 (17)              | 0 (0)               | 10 (24)             | 0.008  |
| MV-RDOS value                               | 2.2 (2.0–2.3)        | 2.1 (2.0–2.2)       | 2.3 (2.0–2.6)       | 0.014  |
| Heart rate, beats/min                       | 92 (84–100)          | 91 (84–98)          | 94 (84–101)         | 0.410  |
| Respiratory rate, cycles/min                | 22 (17–27)           | 19 (14–23)          | 22 (18–28)          | 0.027  |
| Use of neck muscle during inspiration, n (%)| 5 (9)                | 0 (0)               | 5 (15)              | 0.063  |
| Abdominal paradox during inspiration, n (%) | 0 (0)                | 0 (0)               | 0 (0)               | 1.000  |
| Facial expression of fear, n (%)            | 3 (5)                | 0 (0)               | 3 (9)               | 0.251  |
| **At 2-min SBT (n = 58)**                   |                      |                     |                     |        |
| fR/V T, breaths/min/L                       | 64 (49–79)           | 52 (41–72)          | 68 (57–88)          | 0.010  |
| MV-RDOS ≥ 2.6, n (%)                        | 21 (38)              | 3 (12)              | 18 (55)             | <0.001 |
| MV-RDOS value                               | 2.3 (2.2–4.2)        | 2.2 (2.1–2.4)       | 2.6 (2.2–4.5)       | 0.003  |
| Heart rate, beats/min                       | 96 (88–102)          | 92 (86–102)         | 99 (90–104)         | 0.063  |
| Respiratory rate, cycles/min                | 25 (20–30)           | 23 (20–26)          | 28 (24–32)          | 0.005  |
| Use of neck muscle during inspiration, n (%)| 11 (19)              | 1 (4)               | 10 (30)             | 0.016  |
| Abdominal paradox during inspiration, n (%) | 3 (5)                | 0 (0)               | 3 (9)               | 0.251  |
| Facial expression of fear, n (%)            | 10 (17)              | 3 (12)              | 7 (21)              | 0.489  |
| **At 15-min SBT (n = 40)**                  |                      |                     |                     |        |
| fR/V T, breaths/min/L                       | 67 (45–89)           | 50 (40–72)          | 93 (60–141)         | 0.002  |
| MV-RDOS ≥ 2.6, n (%)                        | 21 (53)              | 8 (32)              | 13 (87)             | <0.001 |
| MV-RDOS value                               | 2.7 (2.2–4.3)        | 2.3 (2.1–4.1)       | 4.3 (2.8–5.3)       | <0.001 |
| Heart rate, beats/min                       | 96 (86–102)          | 92 (82–101)         | 97 (88–109)         | 0.492  |
| Respiratory rate, cycles/min                | 25 (21–31)           | 22 (18–26)          | 31 (27–34)          | 0.004  |
| Use of neck muscle during inspiration, n (%)| 12 (30)              | 5 (20)              | 7 (47)              | 0.091  |
| Abdominal paradox during inspiration, n (%) | 5 (13)               | 1 (4)               | 4 (27)              | 0.056  |
| Facial expression of fear, n (%)            | 5 (13)               | 2 (8)               | 3 (20)              | 0.345  |
| **At 30-min SBT (n = 39)**                  |                      |                     |                     |        |
| fR/V T, breaths/min/L                       | 72 (49–107)          | 56 (41–78)          | 94 (60–141)         | 0.006  |
| MV-RDOS ≥ 2.6, n (%)                        | 22 (56)              | 10 (40)             | 12 (86)             | <0.001 |
| MV-RDOS value                               | 3.9 (2.2–4.5)        | 2.4 (2.1–4.2)       | 4.8 (4.1–6.2)       | <0.001 |
| Heart rate, beats/min                       | 98 (89–105)          | 93 (87–103)         | 101 (98–116)        | 0.061  |
| Respiratory rate, cycles/min                | 27 (22–32)           | 24 (21–28)          | 33 (27–38)          | 0.007  |
| Use of neck muscle during inspiration, n (%)| 13 (33)              | 6 (24)              | 7 (50)              | 0.157  |
| Abdominal paradox during inspiration, n (%) | 6 (15)               | 1 (4)               | 5 (36)              | 0.016  |
| Facial expression of fear, n (%)            | 8 (21)               | 3 (12)              | 5 (36)              | 0.108  |

MV-RDOS, mechanical ventilation—respiratory distress observation scale; fR, respiratory rate; VT, expired tidal volume
appropriate, to treat it. Conversely, and to the best of our knowledge, RSBI values has never been proposed to infer clinically important dyspnea in critically ill patients receiving invasive mechanical ventilation.

**Conclusion**

MV-RDOS, an observational clinical corollary to dyspnea might be useful to refine readiness-to-wean criteria. In patient who entered in a SBT, the MV-RDOS might be useful also for early SBT discontinuation in those who will certainly failed the SBT, minimizing exposition to unnecessary respiratory suffering and its associated burden. Such clinical approach may be integrated in a more general goal of care centered on patient comfort and limiting traumatic experience of the ICU stay [28].

Performance and inter-rater reliability of the MV-RDOS in predicting SBT outcome should be confirmed in multicenter study.

**Abbreviations**

AUC: Area under the curve; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; RR: Respiratory rate; ICU: Intensive care unit; MV-RDOS: Mechanical Ventilation—Respiratory Distress Observation Scale; OR: Odds ratio; ROC: Receiver operating curve; RSBI: Rapid shallow breathing index; SAPS II: Simplified acute physiology score II; SBT: Spontaneous breathing trial; SOFA: Sequential Organ Failure Assessment; VT: Expired tidal volume.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-04028-7.

**Additional file 1.** Spontaneous breathing trial (SBT) failure criteria and Respiratory distress assessment over the spontaneous breathing trial (SBT).

**Acknowledgments**

None.

**Author contributions**

Conceptualization/Methodology: MD, ER, M-CN, JM, TS, AD, MD. Analysis/Statistics-software: MD, ER, M-CN, TS, AD, MD. Data acquisition/curation: MD, ER, M-CN, EM, MD. Data interpretation: MD, ER, JM, EM, CM-P, TS, AD, MD. Writing original draft: MD, JM, EM, CM-P, TS, AD, MD. Approval original draft: MD, ER, M-CN, JM, EM, CM-P, TS, AD, MD. All authors read and approved the final manuscript.

**Funding**

This study was supported by a grant from the French Intensive Care Society and the French Society of Pulmonology (co-award).

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Comité de Protection des Personnes du Sud Ouest et Outre Mer 4 (RCB ID: 2018-A00176-49). Written and oral information about the study was given to patients or their families prior enrolment. Informed consent was obtained from all patients or their relatives.

**Consent for publication**

Not applicable.

**Competing interests**

Maxens Decavèle reports personal fees (for congress registration) from ISIS Medical. Thomas Similowski reports personal fees from AstraZeneca France, personal fees from Boehringer Ingelheim France, personal fees and non-financial support from Novartis France, personal fees from TEVA France, personal fees from Chiesi France, personal fees from Lungpacer Inc, personal fees from ADEP Assistance, grants from Air Liquide Medical Systems, outside the submitted work: Alexandre Demoule reports grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees and non-financial support from Fisher & Paykel, grants from French Ministry of Health, personal fees from Getinge, grants, personal fees and non-financial support from Respiron, grants, personal fees and non-financial support from Respiron, personal fees from Lowenstein, personal fees from Gilead, outside the submitted work: Martin Dres reports expertise fees, travel expenses, research contract from Lungpacer, research contract from Bioserenity, and congress registration fees from Dräger, outside the submitted work. Capucine

---

**Fig. 3** Performance of the Mechanical Ventilation—Respiratory Distress Observation Scale (MV-RDOS, black) and the rapid shallow breathing index (RSBI, grey) recorded before, at 2-min and at 15-min of a spontaneous breathing trial (SBT) to predict SBT failure. AUC—area under receiver operating curve.
Morélot-Panzini reports personal fees from Astra-Zeneca, GSK, SOS Oxygène, ADEP, ISIS, Resmed, Chiesi, Menarini, Visiosal, Air Liquide, Lowenstein, Fisher & Paykel, outside the submitted work. Julien Mayaux reports personal fees (for congress registration) from Gilead France. Emmanuel Ro zenberg, Elise Morawiec and Marie-Cécile Niérat, have no conflicts of interests to declare.

Author details
1 INSERM, UMR1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, 75005 Paris, France. 2 APHP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service Médecine Intensive et Réanimation (Département R3S), 75013 Paris, France. 3 APHP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie (Département R3S), 75013 Paris, France. 4 APHP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Département R3S, 75013 Paris, France.

Received: 10 March 2022 Accepted: 19 May 2022 Published online: 06 June 2022

References
1. Böles JM, Bion J, Connors A, et al. Weaning from mechanical ventilation. Eur Respir J. 2009;34:503–56.
2. Ely EW, Baker AM, Dungan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med. 1996;335:1864–9.
3. Cappati KR, Tonella RM, Damascena AS, et al. Interobserver agreement rate of the spontaneous breathing trial. J Crit Care. 2013;28:62–8.
4. Thille AW, Boissier F, Ben Ghezala H, et al. Risk factors for and prediction of the caregivers of extubation failure in ICU patients: a prospective study. Crit Care Med. 2015;43:613–20.
5. Béduneau G, Pham T, Schortgen F, et al. Epidemiology of weaning outcome according to a new definition. The WIND study. Am J Respir Crit Care Med. 2017;195:772–83.
6. Tobin MJ. Extubation and the myth of “minimal ventilator setting.” Am J Respir Crit Care Med. 2012;185:435–52.
7. Perren A, Previsdomini M, Llamas M, et al. Patients’ prediction of extubation success. Intensive Care Med. 2010;36:2045–52.
8. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.
9. Lanning RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol. 2009;167:53–60.
10. Purro A, Appendini L, De Gaetano A, et al. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am J Respir Crit Care Med. 2000;161:1115–23.
11. Haugdahl HS, Stortl SL, Meland B, et al. Underestimation of patient breathlessness by nurses and physicians during a spontaneous breathing trial. Am J Respir Crit Care Med. 2015;192:1440–8.
12. Chen YJ, Hwang SL, Li CR, et al. Depressed ventilator dependence and psychological distress during ventilator weaning and the related outcomes. J Psychosom Res. 2017;101:10–6.
13. Knebel AR, Janson-Bjerklie SL, Malley JD, et al. Comparison of breathing comfort during weaning with two ventilatory modes. Am J Respir Crit Care Med. 1994;149:194–8.
14. Leung P, Jubran A, Tobin MJ. Comparison of assisted ventilator modes on triggering, patient effort, and dyspnea. Am J Respir Crit Care Med. 1997;155:1940–8.
15. Vitacca M, Ambrosino N, Clini E, et al. Physiological response to pressure support ventilation delivered before and after extubation in patients not capable of totally spontaneous autonomous breathing. Am J Respir Crit Care Med. 2001;164:638–41.
16. Dres M, Simlowski T, Goligher EC, et al. Dyspnea and respiratory muscles ultrasound to predict extubation failure. Eur Respir J. 2021;19:2100002.
17. Nelson JE, Meier DE, Oei EJ, et al. Self-reported symptom experience of critically ill cancer patients receiving intensive care. Crit Care Med. 2001;29:277–82.
18. Gentzler ER, Derry H, Cuyang DJ, et al. Underdetection and undertreatment of dyspnea in critically ill patients. Am J Respir Crit Care Med. 2019;199:1377–84.
19. Binks AP, Desjardín S, Riker R. ICU clinicians underestimate breathing discomfort in ventilated subjects. Respir Care. 2017;62:150–5.
20. Campbell ML, Templin T, Walsh J. A Respiratory Distress Observation Scale for patients unable to self-report dyspnea. J Palliat Med. 2010;13:285–90.
21. Persichini R, Gay F, Schmidt M, et al. Diagnostic accuracy of respiratory distress observation scales as surrogates of dyspnea self-report in intensive care unit patients. Anesthesiology. 2015;123:830–7.
22. Decavelle M, Gay F, Persichini R, et al. The Mechanical Ventilation—Respiratory Distress Observation Scale as a surrogate of self-reported dyspnea in intubated patients. Eur Respir J. 2018;52:1800598.
23. Dres M, Rozenberg E, Morawiec E, et al. Diaphragm dysfunction, lung aeration loss and weaning-induced pulmonary oedema in difficult-to-wean patients. Ann Intensive Care. 2021;11:99.
24. Twaddle ML, Maxwell TL, Cassel JB, et al. Palliative care benchmarks from academic medical centers. J Palliat Med. 2007;10:868–96.
25. Mahul M, Jung B, Galia F, et al. Spontaneous breathing trial and post-extubation work of breathing in morbidly obese critically ill patients. Crit Care. 2016;20:346.
26. Sklar MC, Burns K, Rittayamai N, et al. Effort to breathe with various spontaneous breathing trial techniques. A physiologic meta-analysis. Am J Respir Crit Care Med. 2017;195:1477–85.
27. Schmidt M, Demoule A, Pelosi P, et al. Dyspnea in mechanically ventilated critically ill patients. Crit Care Med. 2011;39:2059–65.
28. Demoule A, Hajage D, Messika J, et al. Prevalence, intensity and clinical impact of dyspnea in critically ill patients receiving invasive ventilation. Am J Respir Crit Care Med. 2022. Epub ahead of print.
29. Campbell ML. Fear and pulmonary stress behaviors to an asphyxial threat across cognitive states. Res Nurs Health. 2007;30:572–83.
30. Campbell ML, Yaraní HM, Mendez A. A two-group trial of a terminal ventilator withdrawal algorithm: pilot testing. J Palliat Med. 2015;18:781–5.
31. Robert R, Le Gouge A, Kentish-Barnes N, et al. Terminal weaning or immediate extubation for withdrawing mechanical ventilation in critically ill patients (the ARREVE observational study). Intensive Care Med. 2017;43:1793–807.
32. Herzog M, Succe J, Van Dien I, et al. Reduced neural gating of respiratory sensations is associated with increased dyspnoea perception. Eur Respir J. 2018;52:1800559.
33. Parthasarathy S, Jubran A, Laghi F, et al. Sternomastoid, ribcage and expiratory muscle activity during weaning failure. J Appl Physiol. 2007;103:140–7.
34. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46:e825–73.
35. Demoule A, Simlowski T. Respiratory suffering in the ICU: time for our next great cause. Am J Respir Crit Care Med. 2019;199:1302–4.
36. Subirá C, Hernández G, Vázquez A, et al. Impact of pressure support vs T-piece ventilation strategies during spontaneous breathing trials on successful extubation among patients receiving mechanical ventilation: a randomized clinical trial. JAMA. 2019;321:2175–82.
37. Trivedi V, Chaudhuri D, Jinah R, et al. The usefulness of the rapid shallow breathing index in predicting successful extubation: a systematic review and meta-analysis. Chest. 2022;161:97–111.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.